Arabic Arabic English English French French German German
dark

Anocca Raises $47m in a Series B Financing to Advance Its Industrialised Approach to TCR-T Cellular Immunotherapy

Anocca AB, a leader in unlocking the potential of T-cell immunotherapy to deliver transformative therapeutics for cancer, announced the closing of a USD 47 million Series B financing to further advance the company’s industrialised cellular biology platform and progress its pipeline of TCR-T cellular therapies into Phase I/IIa clinical trials. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Welocalize Celebrates its 19th Acquisition as Next Level Globalization Joins

Next Post

Hiscox boss Bronek Masojada to retire – successor revealed

Related Posts
Total
0
Share